Medtronic CEO weighs in on US vs EU regulation debate; defends handling of Infuse crisis
This article was originally published in Clinica
Medtronic CEO Omar Ishrak believes the US FDA's approval process takes too long, and has suggested it should adopt a similar system to that used in Europe. In an interview published in the Financial Times, Mr Ishrak noted that in Europe, medical devices reach the market 18-24 months sooner than in the US, because the "response time is quicker, the clinical trial cycle is quicker, and maybe some of the barriers [to market entry] are less stringent".
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.